Safety, tolerability, and efficacy of orally administered cannabinoids in MS

被引：165

作者：

Killestein, J

Hoogervorst, ELJ

Reif, M

Kalkers, NF

van Loenen, AC

Staats, PGM

Gorter, RW

Uitdehaag, BMJ

Polman, CH

机构：

[1] VU Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands

[2] European Inst Oncol & Immunol Res, Berlin, Germany

[3] TNO Prevent & Hlth, Div Publ Hlth, Leiden, Netherlands

[4] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA 94143 USA

来源：

NEUROLOGY | 2002年 / 58卷 / 09期

关键词：

D O I：

10.1212/WNL.58.9.1404

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Delta(9)-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression.

引用

页码：1404 / 1407

页数：4

共 10 条

[1]

[Anonymous], J CLIN PHARMACOL

[2]

ASHWORTH B, 1964, PRACTITIONER, V192, P540

[3] Cannabinoids control spasticity and tremor in a multiple sclerosis model [J].

Baker, D ;

Pryce, G ;

Croxford, JL ;

Brown, P ;

Pertwee, RG ;

Huffman, JW ;

Layward, L .

NATURE, 2000, 404 (6773) :84-87

[4] Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'? [J].

Di Marzo, V ;

Bifulco, M ;

De Petrocellis, L .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (06) :195-197

[5] SHORT-TERM EFFECTS OF SMOKING MARIJUANA ON BALANCE IN PATIENTS WITH MULTIPLE-SCLEROSIS AND NORMAL VOLUNTEERS [J].

GREENBERG, HS ;

WERNESS, SAS ;

PUGH, JE ;

ANDRUS, RO ;

ANDERSON, DJ ;

DOMINO, EF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :324-328

[6]

Iversen L, 2000, SCI MARIJUANA

[7] A health-related quality of life questionnaire for multiple sclerosis patients [J].

Pfennings, LEMA ;

Van der Ploeg, HM ;

Cohen, L ;

Bramsen, I ;

Polman, CH ;

Lankhorst, GJ ;

Vleugels, L .

ACTA NEUROLOGICA SCANDINAVICA, 1999, 100 (03) :148-155

[8] Recommendations from the national multiple sclerosis society clinical outcomes assessment task force [J].

Rudick, R ;

Antel, J ;

Confavreux, C ;

Cutter, G ;

Ellison, G ;

Fischer, J ;

Lublin, F ;

Miller, A ;

Petkau, J ;

Rao, S ;

Reingold, S ;

Syndulko, K ;

Thompson, A ;

Wallenberg, J ;

Weinshenker, B ;

Willoughby, E .

ANNALS OF NEUROLOGY, 1997, 42 (03) :379-382

[9]

Stewart A. L., 1992, MEASURING FUNCTIONIN

[10]

UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39

← 1 →